SS-31 (Elamipretide) vs Palmitoyl Tetrapeptide-7

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

SS-31 (Elamipretide)

SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.

Full details →

Palmitoyl Tetrapeptide-7

Palmitoyl Tetrapeptide-7 is an anti-inflammatory peptide that reduces IL-6 secretion. Combined with Palmitoyl Tripeptide-1, it forms Matrixyl 3000, addressing both collagen production and inflammation.

Full details →

Side-by-Side Comparison

AspectSS-31 (Elamipretide)Palmitoyl Tetrapeptide-7
MechanismConcentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency.Suppresses interleukin-6 (IL-6) production, reducing inflammation that contributes to skin aging. The anti-inflammatory effect complements collagen-stimulating peptides.
Typical DosageClinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily.Topical: Usually combined with Palmitoyl Tripeptide-1 at similar concentrations (2-4%) in the Matrixyl 3000 complex.
AdministrationCan be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions.Topical application with other anti-aging actives. The palmitoyl group enhances delivery into the skin.
Side EffectsGenerally well-tolerated. Clinical trials reported injection site reactions and occasional headache.Excellent tolerability profile. Anti-inflammatory properties may actually soothe sensitive skin.
Best For

Key Differences

Unique to SS-31 (Elamipretide):

Unique to Palmitoyl Tetrapeptide-7:

Ready to Learn More?